Thromboembolism prophylaxis with dabigatran leads to lower perioperative blood loss than with dalteparin in primary knee arthroplasty

Comparison of minor bleeding complications using dabigatran or enoxaparin after cemented total hip arthroplasty

BACKGROUND

Orally administered chemical thromboprophylactic agents for total hip replacement (THR) have become popular in recent years. Certain clinical trials suggest that the efficacy and the risk of major bleeding after administration of direct thrombin inhibitor dabigatran etexilate are equivalent to the clinical trial comparator, subcutaneous low-molecular-weight heparin enoxaparin. Our aim was to compare and evaluate the incidence of minor haemorrhagic and soft-tissue adverse effects of enoxaparin and dabigatran.

MATERIALS AND METHODS

122 patients who were treated by elective cemented primary THR were enrolled in our quasi-randomised study. Two groups were formed according to which perioperative thromboprophylactic agent was used: 61 patients in enoxaparin group versus 61 patients in dabigatran group. Thigh volume changes, calculated perioperative blood loss, area of haematoma, wound bleeding, duration of wound discharge and intensity of serous wound discharge on postoperative day 3 and day 7 were recorded.

RESULTS

The duration and intensity of serous wound discharge differed significantly between the two groups. Duration of wound discharge after drain removal was 2.2 (±2.7) days in the dabigatran group and 1.2 (±1.9) days in the enoxaparin group (p < 0.05). Significant increase in serous discharge was found in the dabigatran group (p < 0.05) on third and seventh postoperative days compared to the enoxaparin group.

CONCLUSION

Both thromboprophylactic agents were found to have appropriate antithrombotic effects after THR. However, dabigatran was associated with an increased incidence of prolonged serous wound discharge, which might cause longer hospitalization and might instigate the use of prolonged antibiotic prophylaxis.

The effects of a tourniquet used in total knee arthroplasty: a meta-analysis

Background

The purpose of this research is to evaluate the effects of a tourniquet in total knee arthroplasty (TKA).

Methods

The study was done by randomized controlled trials (RCTs) on the effects of a tourniquet in TKA. All related articles which were published up to June 2013 from Medline, Embase, and Cochrane Central Register of Controlled Trails were identified. The methodological quality of the included studies was assessed by the Physiotherapy Evidence Database (PEDro) scale. The meta-analysis was performed using Cochrane RevMan software version 5.1.

Results

Thirteen RCTs that involved a total of 689 patients with 689 knees were included in the meta-analysis, which were divided into two groups. The tourniquet group included 351 knees and the non-tourniquet group included 338 knees. The meta-analysis showed that using a tourniquet in TKA could reduce intraoperative blood loss (weighted mean difference (WMD), -198.21; 95% confidence interval (CI), -279.82 to -116.60; P < 0.01) but did not decrease the calculated blood loss (P = 0.80), which indicates the actual blood loss. Although TKA with a tourniquet could save the operation time for 4.57 min compared to TKA without a tourniquet (WMD, -4.57; 95% CI, -7.59 to -1.56; P < 0.01), it had no clinical significance. Meanwhile, the use of tourniquet could not reduce the possibility of blood transfusion (P > 0.05). Postoperative knee range of motion (ROM) in tourniquet group was 10.41° less than that in the non-tourniquet group in early stage (≤10 days after surgery) (WMD, -10.41; 95% CI, -16.41 to -4.41; P < 0.01). Moreover, the use of a tourniquet increased the risk of either thrombotic events (risk ratio (RR), 5.00; 95% CI, 1.31 to 19.10; P = 0.02) or non-thrombotic complications (RR, 2.03; 95% CI, 1.12 to 3.67; P = 0.02).

Conclusions

TKA without a tourniquet was superior to TKA with a tourniquet in thromboembolic events and the other related complications. There were no significant differences between the two groups in the actual blood loss. TKA with a tourniquet might hinder patients' early postoperative rehabilitation exercises.

Risk modification for postoperative pulmonary embolism: timing of postoperative prophylaxis

INTRODUCTION

Risk factors for postoperative pulmonary embolism can often not be modified and are patient related. The purpose of this case control study was to identify possible modifiable risk factors for postoperative pulmonary embolism.

MATERIALS AND METHODS

We undertook a case control study among 210,269 patients who underwent noncardiac surgery from 2000 to 2009 at the Erasmus Medical Center. Case subjects were all 199 (0.09%) patients who experienced a pulmonary embolism within 30 days after surgery. From the remaining patients, 1 control was selected for each case and was stratified according to calendar year. For cases and controls, information was obtained regarding risk factors and the type and dose of thromboprophylaxis as well as the time of postoperative initiation.

RESULTS

Overweight, surgery for malignancy, a history of cerebrovascular disease and a history of thromboemblic diseases, intraoperative blood transfusions and delayed use of thromboprophylaxis were more common in cases than in controls. After correction delayed use of thromboprophylaxis was associated with a 4 fold increased risk (OR 4.1; 95% CI: 2.1 - 7.7) for postoperative pulmonary embolism.

CONCLUSION

Delayed timing of postoperative thromboprophylaxis is an important modifiable risk factor for postoperative pulmonary embolism after noncardiac surgery. This study emphasises the importance of on time administration of thromboprophylaxis.